10 Key Insights into Pharma's Reputation: Progress and Persistent Challenges

The pharmaceutical industry has long walked a tightrope between innovation and public perception. In 2025, a comprehensive survey by PatientView reveals a modest uptick in how patient groups view drugmakers—but beneath the surface, concerns about affordability and genuine patient focus remain stubbornly high. This article unpacks the 10 most crucial findings from the study, offering a balanced look at where pharma stands and where it must improve.

1. A Slight Reputation Bump: 57% Now Rate Pharma as 'Excellent' or 'Good'

For the first time in two years, the pharmaceutical industry's reputation among patient groups has inched upward. According to PatientView's survey of over 2,400 patient organizations across 35 countries, 57% now describe drugmakers' work in developing and providing medicines as either 'excellent' or 'good.' That one-percentage-point rise from 56% in 2024 brings the industry back to its 2023 level, though it still lags behind the 60% rating recorded in 2022. The improvement is modest but suggests that some efforts to rebuild trust are starting to register.

2. Patient Centricity and Safety Drive the Positive Shift

The survey identifies two key factors behind the reputation uptick: patient centricity—defined as prioritizing patient needs in every aspect of drug development—and a strong commitment to patient safety. Companies that have invested in patient advisory boards, co-development programs, and transparent safety reporting are being rewarded with higher trust scores. However, the gains are uneven, with smaller biotech firms often outperforming larger corporations in these areas, according to industry observers.

3. Access and Pricing Concerns Still Cloud the Picture

Despite the overall improvement, the survey reveals that access and pricing remain the Achilles' heel for pharma. Nearly two-thirds of patient groups cited high drug costs as a major barrier to care, echoing findings from previous years. Even as companies tout innovative therapies, the reality of who can afford them continues to erode goodwill. This disconnect between product value and affordability is a persistent source of tension, with some patient advocates calling for more transparent pricing models and expanded assistance programs.

4. 47 Companies Rated, But Only a Few Stand Out

PatientView evaluated 47 pharmaceutical companies in depth. The survey's methodology allowed patient groups to rate each company individually, creating a competitive landscape. While a handful of firms—namely those with strong rare-disease portfolios or robust patient engagement programs—scored well above the industry average, many others fell below the 50% threshold for 'excellent' or 'good.' This wide dispersion highlights that reputation is not monolithic; actions by individual companies matter greatly.

5. The 'Excellent' Category: What It Takes

To earn an 'excellent' rating from patient groups, companies must demonstrate consistent behavior across multiple dimensions. According to the data, these firms excel in four areas: patient information provision, responsiveness to queries, integrity in communication, and long-term commitment to disease areas. They are also more likely to involve patient groups early in clinical trial design, a practice that builds trust from the ground up.

6. Geographic Variations: A Global but Uneven Picture

The survey spanned 35 countries, revealing notable geographic disparities. Patient groups in Western Europe and North America generally gave higher ratings, while those in parts of Asia and Africa were more critical, citing lower access to medicines and less engagement from companies. These differences underscore the challenge for global pharma: strategies that work in one region may not translate elsewhere, especially where healthcare infrastructure varies widely.

7. The 60% Threshold Remains Elusive

The industry's current 57% rating is still three points shy of the 60% it achieved in 2022—a benchmark that now feels distant. Analysts suggest the decline from 2022 to 2024 was driven by heightened scrutiny over drug pricing and several high-profile lawsuits. To reclaim that level, companies will need to not only maintain current gains but also address structural criticisms around transparency and equitable access.

8. Patient Groups as Powerful Reputation Shapers

Patient organizations are no longer passive observers; they actively shape public opinion and policy. With over 2,400 groups surveyed, the sample size gives this report significant weight. These groups influence everything from clinical trial recruitment to reimbursement decisions. As such, pharma companies ignore them at their peril. The survey results serve as a barometer for the broader sentiment among key opinion leaders in the health ecosystem.

9. The Role of Digital Transparency Tools

One emerging trend noted in the survey is the positive impact of digital platforms that share drug pricing data, clinical trial results, and patient feedback. Companies that have adopted such tools saw higher trust scores, particularly among tech-savvy patient groups. However, adoption is still patchy, and skeptics worry that these tools could be used for marketing rather than genuine transparency. The coming years will test whether digital solutions can bridge the trust gap.

10. The Road Ahead: Recommendations for Pharma

Looking forward, the survey offers a clear roadmap for improvement. PatientView recommends that companies: (a) make patient centricity a core business function, not a PR exercise; (b) implement tiered pricing models to improve access; (c) invest in long-term relationships with patient groups rather than transactional engagements; and (d) publish annual transparency reports. The modest reputation gain suggests patience is possible, but only if actions align with words.

In conclusion, the 2025 PatientView survey paints a nuanced portrait of the pharmaceutical industry—one where small improvements are overshadowed by persistent distrust around cost and access. The 57% approval rating is a start, but not a finish. As patient groups become increasingly vocal and organized, pharma must decide whether to truly partner with them or risk being left behind. The data is in; the choice is now.